Navigation Links
CuraGen to Present CR011-vcMMAE Data at ASCO
Date:5/28/2009

ology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations
'/>"/>
SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... SAN DIEGO, Sept. 21 Aethlon Medical, Inc. ... pioneer in developing therapeutic filtration devices to address ... has reestablished efforts to advance the Aethlon Hemopurifier® ... and purchase of treatment countermeasures against bioterror threats. ...
... to Advance its Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:Aethlon Medical Reestablishes Biodefense Programs 2Aethlon Medical Reestablishes Biodefense Programs 3Aethlon Medical Reestablishes Biodefense Programs 4Aethlon Medical Reestablishes Biodefense Programs 5Aethlon Medical Reestablishes Biodefense Programs 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, ... the National Retail Federation, the largest retail trade association in the world, for her ... owners to be named as such. According to the NRF’s website, Retail Champions are ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic and ... has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations in ... , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as the ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, ... free to download on the Apple AppStore. , The app is designed to ... thus acting as a tool to view personal health and use this information for ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... ... with HCG Diet Drops , ... 14, 2010 -- It is no secret that obesity has reached epidemic proportions in our country. ... as a result of the extra pounds. , , ,But thanks to the HCG ...
... ... accident claims service National Accident Helpline warns of the dangers of cycling injuries and urges caution ... (PRWEB) June 14, ... to prevent cycling injuries now the improving weather is seeing an increasing number of people take ...
... ... the amazing true tale of one man,s journey of growing up in poverty ... a college degree. He decided to make a difference in the lives ... numerous local and national awards for his community work. He took his ...
... ... software is pleased to welcome Click2Scan Ltd. a document scanning specialist, and document management software ... ... Ltd. www.click2scan.co.uk with offices in Wiltshire and London is one of the fastest ...
... ... Jazz Festival, , ... Newport, R.I. (PRWEB) June 14, 2010 -- New Festival Productions today announced that discounted ... the 2010 CareFusion Newport Jazz Festival in Newport, RI, August 6-8. Generously donated by ...
... ... in cosmetic, facial plastic, and reconstructive surgery, understands that women need options. With an ... an alternative method to breast implant surgery. Natural breast augmentation allows patients the opportunity ... ...
Cached Medicine News:Health News:Thousands Drop The Weight For Good with HCG Diet Drops 2Health News:Break The Injury Cycle, Says National Accident Helpline 2Health News:Celebrated Father Overcame Poverty and Mental Illness to Help His Son Earn a Scholarship to Harvard 2Health News:FileHold Document Management Software welcomes Click2ScanLtd. as a Value Added Re-sellers in the UK 2Health News:CareFusion Newport Jazz Festival Discounts Tickets for Health Care Practitioners 2Health News:Del Mar Plastic Surgeon Dr. Maurice Sherman Now Offering Natural Breast Implant Alternatives 2
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Regular tip. 1 mm x 13 mm. Serrated. Insulated....
Colibri style with 1.5 mm long angled tip and 0.12 mm teeth. Serrated handles with polished finish....
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight....
Medicine Products: